Claims for Patent: 4,160,021

Summary for Patent: 4,160,021

Title:	Substituted 2H-pyran-2,6(3H)-dione derivatives
Abstract:	Substituted 2H-pyran-2,6(3H)-dione derivatives useful in the treatment of allergic conditions are prepared by reaction of 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one with an appropriate aniline.
Inventor(s):	Snader; Kenneth M. (Hatboro, PA)
Assignee:	SmithKline Corporation (Philadelphia, PA)
Application Number:	05/885,142
Patent Claims:	1. A compound represented by the formula: ##STR5## wherein: R.sub.1 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl; R.sub.2 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl, and when R.sub.1 is lower alkoxy carbamoyl, R.sub.2 is also hydrogen, and when R.sub.2 is not hydrogen R.sub.1 and R.sub.2 are the same; and the lower alkoxy moieties have 1 or 2 carbon atoms, or a mono- or di-alkali metal salt of said compound. 2. A compound according to claim 1 in which R.sub.1 and R.sub.2 are ethoxyoxamoyl. 3. A compound according to claim 1 in which R.sub.1 and R.sub.2 are hydroxyoxamoyl. 4. A compound according to claim 1 in which R.sub.1 and R.sub.2 are ethoxycarbamoyl. 5. A compound according to claim 1 in which R.sub.1 is ethoxycarbamoyl and R.sub.2 is hydrogen. 6. A pharmaceutical composition for inhibiting the symptoms of asthma comprising a nontoxic pharmaceutical carrier or diluent and an amount sufficient to produce said inhibition of a compound represented by the formula: ##STR6## wherein: R.sub.1 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl; R.sub.2 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl, and when R.sub.1 is lower alkoxy carbamoyl, R.sub.2 is also hydrogen, and when R.sub.2 is not hydrogen R.sub.1 and R.sub.2 are the same; and the lower alkoxy moieties have 1 or 2 carbon atoms, or a mono- or di-alkali metal salt of said compound. 7. A pharmaceutical composition according to claim 6 in a form suitable for administration by inhalation. 8. A pharmaceutical composition according to claim 6 comprising a solution or suspension of the active ingredient in sterile water. 9. A pharmaceutical composition according to claim 6 in the form of an aerosol formulation. 10. A pharmaceutical composition according to claim 6 in which the pharmaceutical carrier or diluent is a solid. 11. A pharmaceutical composition according to claim 6 in which R.sub.1 and R.sub.2 are ethoxyoxamoyl. 12. A pharmaceutical composition according to claim 6 in which R.sub.1 and R.sub.2 are hydroxyoxamoyl. 13. A pharmaceutical composition according to claim 6 in which R.sub.1 and R.sub.2 are ethoxycarbamoyl. 14. A pharamceutical composition according to claim 6 in which R.sub.1 is ethoxycarbamoyl and R.sub.2 is hydrogen. 15. A pharmaceutical composition according to claim 6 in dosage unit form and in which the active ingredient is in an amount of from about 0.5 to about 500 mg. per dosage unit. 16. A method of inhibiting the symptoms of asthma which comprises administering to an animal in need of said inhibition a therapeutically effective amount for producing said inhibition of a compound represented by the formula: ##STR7## wherein: R.sub.1 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl; R.sub.2 is lower alkoxy oxamoyl, hydroxyoxamoyl, lower alkoxy carbamoyl, and when R.sub.1 is lower alkoxy carbamoyl, R.sub.2 is also hydrogen, and when R.sub.2 is not hydrogen R.sub.1 and R.sub.2 are the same; and the lower alkoxy moieties have 1 or 2 carbon atoms, or a mono-or di-alkali metal salt of said compound. 17. The method according to claim 16 in which the active ingredient is administered in a daily dosage regimen of from about 0.5 mg. to about 2000 mg.

Details for Patent 4,160,021

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		1997-05-23